Receive The Newest Study Notifications

AVEO Oncology and Biodesix Announce Results from Phase 1b Study of Ficlatuzumab, Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer

by Lance Smith | Jan 27, 2020 | Study Scavenger Clinical Trial Recruitment Platform

– Data Presented at the 2020 ASCO GI Cancers Symposium – CAMBRIDGE, Mass. & BOULDER, Colo.–(BUSINESS WIRE)–AVEO Oncology (NASDAQ: AVEO) and Biodesix, Inc. today announced the presentation of results from an investigator-sponsored Phase 1b...

Risdiplam (RG7916) Pivotal FIREFISH Study Demonstrated Statistically Significant Improvement in Infants with Type 1 Spinal Muscular Atrophy

by Lance Smith | Jan 24, 2020 | Study Scavenger Clinical Trial Recruitment Platform

Risdiplam (RG7916) Pivotal FIREFISH Study Demonstrated Statistically Significant Improvement in Infants with Type 1 Spinal Muscular Atrophy  – Study meets primary endpoint in patients living with type 1 SMA – – To date, more than 400 patients have...

Tonix Pharmaceuticals to Present Results from Preclinical Study of TNX-801 in a Poster Presentation at the 2020 American Society for Microbiology (ASM) Biothreats Conference

by Lance Smith | Jan 24, 2020 | Study Scavenger Clinical Trial Recruitment Platform

NEW YORK, Jan. 23, 2020 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals, Inc. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that it will be presenting preclinical results of TNX-801 in a poster at the 2020 ASM...

Exelixis Announces Results for Combination of Cabozantinib and Nivolumab With or Without Ipilimumab in Advanced Hepatocellular Carcinoma

by Lance Smith | Jan 24, 2020 | Study Scavenger Clinical Trial Recruitment Platform

– Data from the CheckMate 040 trial presented at the 2020 American Society of Clinical Oncology’s Gastrointestinal Cancers Symposium – January 24, 2020 07:30 AM Eastern Standard Time ALAMEDA, Calif.–(BUSINESS WIRE)–Exelixis, Inc. (NASDAQ: EXEL) today...

Ascletis Received Approval of Clinical Trials in HBV Patients for ASC22, a Subcutaneously Administered PD-L1 Antibody

by Lance Smith | Jan 23, 2020 | Study Scavenger Clinical Trial Recruitment Platform

HANGZHOU and SHAOXING, China, Jan. 22, 2020 /PRNewswire/ — Ascletis Pharma Inc. (Ascletis, 1672.HK) announces today the approval for ASC22 to conduct clinical trials in chronic hepatitis B patients in China from China’s National Medical Products...

Risdiplam (RG7916) Pivotal FIREFISH Study Demonstrated Statistically Significant Improvement in Infants with Type 1 Spinal Muscular Atrophy

by Lance Smith | Jan 23, 2020 | Study Scavenger Clinical Trial Recruitment Platform

Study meets primary endpoint in patients living with type 1 SMA To date, more than 400 patients have been treated with risdiplam across all studies, with no treatment related safety findings leading to study withdrawal in any risdiplam trial Risdiplam PDUFA expected...